Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Open, Comparative, Randomized Study of the Efficacy and Safety Evaluation of the Mexidol® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

NCT06437639 is registered in ClinicalTrials.gov with Pharmasoft as lead sponsor.

NCT NCT06437639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06437639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Open, Comparative, Randomized Study of the Efficacy and Safety Evaluation of the Mexidol® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
Lead sponsor
Pharmasoft
Phase
Phase 4
Overall status
Completed
Start date
September 15, 2023
Completion date
February 2, 2024
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary open-angle glaucoma (poag)